PP_1170x120_10-25-21

Merz North America

FDA approves Xeomin for adult patients with sialorrhea

FDA approves Xeomin for adult patients with sialorrhea

RALEIGH, N.C. — Merz North America announced  that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients. Xeimin is the first and only neurotoxin with this approved indication in the U.S.   “Until now, there